Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AstraZeneca | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

AstraZeneca

AZ posted flat revenues, but a boost in earnings in 2Q09

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca 2Q09

2Q Revenues: $8.0 billion (flat)

2Q Earnings: $2.4 billion (+70%)

YTD Revenues: $15.7 billion (flat)

YTD Earnings: $4.0 billion (+21%)

Comments: Two generic marketers of Toprol-XL withdrew from the U.S. market,and the introduction of generic Casodex was delayed, giving AZ a boost. Nexium posted a 6% drop in sales in 2Q09 to $1.2 billion, while Crestor posted a 23% rise to $1.1 billion. Nexium sales rose 12% to $1.2 billion. Seloken/Toprol-XL sales doubled to $417 million. Symbicort sales were up 6% to $551 million.

Sign up today for Contracting & Outsourcing 2009!

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters